OM1 to Present Breakthrough Research on GLP-1 Agonists and Suicidal Ideation at ISPOR 2025 BOSTON—(BUSINESS WIRE)—OM1, a leading provider of real-world data and AI-driven insights in mental health for life sciences, will unveil groundbreaking research at ISPOR 2025. The study, conducted by Jessica Probst, OM1’s Principal of Real World Evidence, examines the relationship between Glucagon-like Peptide 1 Receptor Agonists (GLP-1s) and suicidal ideation (SI). The poster presentation will take place during the ISPOR 2025 conference on Wednesday, May 14, from 4:00 PM to 7:00 PM. A dedicated discussion period will follow from 6:00 PM to 7:00 PM. Key Findings GLP-1 receptor agonists are widely used to treat both diabetes and obesity. Recent concerns have raised questions about their potential link to suicidal ideation. However, OM1's real-world study has found that despite label warnings, there is no significant increase in the prevalence of suicidal ideation after initiating GLP-1 therapy in either therapeutic population. Why It Matters The package labels for GLP-1s used in obesity treatments include a warning for suicidal ideation, which is absent on those indicated for diabetes. This discrepancy has sparked debates among healthcare professionals and researchers. OM1’s findings contribute to the ongoing discussion, suggesting that the suicidal ideation warning for obesity treatments might be an unnecessary caution, potentially deterring patients from accessing essential care. This barrier can be particularly concerning for individuals seeking obesity treatment, a condition often accompanied by stigma and discrimination. Methodology Traditionally, claims-based datasets tend to underreport or omit suicidal ideation. To address this limitation, OM1 utilized advanced natural language processing (NLP) techniques to analyze unstructured clinician notes. This approach provided a more comprehensive and detailed understanding of patient mental health, capturing subtleties that conventional methods might miss. The study's methods and results underscore the critical role of AI and real-world data (RWD) in enhancing pharmacovigilance and ensuring public health safety. Implications for Stakeholders For pharmaceutical companies, healthcare providers, and regulatory bodies, OM1's research offers valuable insights that could influence future labeling practices and treatment recommendations. The study also highlights the importance of using advanced technologies to gather and interpret real-world data, providing a more accurate picture of drug safety and efficacy. About OM1 OM1 is at the forefront of healthcare innovation, leveraging insights-driven technology and data to advance personalized medicine, evidence generation, and real-world evidence (RWE) research. The company’s next-generation AI platforms, deep longitudinal data, and renowned thought leadership are guided by a team of experienced scientists, engineers, researchers, and clinicians. With over 30 years of expertise in RWE, OM1 continues to drive forward the integration of technology and healthcare to improve patient outcomes and equity in medical treatments.